CD30 expression in de novo diffuse large B-cell lymphoma: A population-based study from British Columbia

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 608-617

  Slack, Graham W ^a   Steidl, Christian ^a   Sehn, Laurie H ^a   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

CD30; Diffuse large B cell lymphoma; Doxorubicin; Epstein Barr virus; Immunohistochemistry; Prednisone therapy; Rituximab plus cyclophosphamide; Vincristine

Indexed keywords

CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FORMALDEHYDE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION PROFILING; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME; VERY ELDERLY; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA MICROARRAY; EPIDEMIOLOGY; FOLLOW UP; GENE EXPRESSION REGULATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRITISH COLUMBIA; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 84925226282     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13085     Document Type: Article

References (30)

1. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J. Jr, Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. & Staudt, L.M. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-511.
2. Bartlett, N.L., Sharman, J.P., Oki, Y., Advani, R.H., Bello, C.M., Winter, J.N., Yang, Y., Kennedy, D.A. & Jacobsen, E.D. (2013) A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-hodgkin lymphomas: interim results in patients with DLBCL and other B-Cell lymphomas. Blood, 122, 848.
3. Beltran, B.E., Castillo, J.J., Morales, D., de Mendoza, F.H., Quinones, P., Miranda, R.N., Gallo, A., Lopez-Ilasaca, M., Butera, J.N. & Sotomayor, E.M. (2011) EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. American Journal of Hematology, 86, 663-667.
4. Campuzano-Zuluaga, G., Cioffi-Lavina, M., Lossos, I.S. & Chapman-Fredricks, J.R. (2013) Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. Leukaemia & Lymphoma, 54, 2405-2411.
5. Chiarle, R., Podda, A., Prolla, G., Gong, J., Thorbecke, G.J. & Inghirami, G. (1999) CD30 in normal and neoplastic cells. Clin Immunol, 90, 157-164.
6. Choi, W.W., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., Braziel, R.M., Geng, H., Iqbal, J., Lenz, G., Vose, J.M., Hans, C.P., Fu, K., Smith, L.M., Li, M., Liu, Z., Gascoyne, R.D., Rosenwald, A., Ott, G., Rimsza, L.M., Campo, E., Jaffe, E.S., Jaye, D.L., Staudt, L.M. & Chan, W.C. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clinical Cancer Research, 15, 5494-5502.
7. Choy, E.Y., Siu, K.L., Kok, K.H., Lung, R.W., Tsang, C.M., To, K.F., Kwong, D.L., Tsao, S.W. & Jin, D.Y. (2008) An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. Journal of Experimental Medicine, 205, 2551-2560.
8. de Claro, R.A., McGinn, K., Kwitkowski, V., Bullock, J., Khandelwal, A., Habtemariam, B., Ouyang, Y., Saber, H., Lee, K., Koti, K., Rothmann, M., Shapiro, M., Borrego, F., Clouse, K., Chen, X.H., Brown, J., Akinsanya, L., Kane, R., Kaminskas, E., Farrell, A. & Pazdur, R. (2012) U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clinical Cancer Research, 18, 5845-5849.
9. Durkop, H., Latza, U., Hummel, M., Eitelbach, F., Seed, B. & Stein, H. (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell, 68, 421-427.
10. Gibson, S.E. & Hsi, E.D. (2009) Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Human Pathology, 40, 653-661.
11. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
12. Hill, B.T., Manilich, E.A., Smith, M.R. & Hsi, E.D. (2013) CD30 immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype. Blood, 122, 4318.
13. Hoeller, S., Tzankov, A., Pileri, S.A., Went, P. & Dirnhofer, S. (2010) Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Human Pathology, 41, 352-357.
14. Horie, R. & Watanabe, T. (1998) CD30: expression and function in health and disease. Seminars in immunology, 10, 457-470.
15. Hu, S., Xu-Monette, Z.Y., Balasubramanyam, A., Manyam, G.C., Visco, C., Tzankov, A., Liu, W.M., Miranda, R.N., Zhang, L., Montes-Moreno, S., Dybkaer, K., Chiu, A., Orazi, A., Zu, Y., Bhagat, G., Richards, K.L., Hsi, E.D., Choi, W.W., Han van Krieken, J., Huang, Q., Huh, J., Ai, W., Ponzoni, M., Ferreri, A.J., Zhao, X., Winter, J.N., Zhang, M., Li, L., Moller, M.B., Piris, M.A., Li, Y., Go, R.S., Wu, L., Medeiros, L.J. & Young, K.H. (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 121, 2715-2724.
16. Lee, S.Y., Kandala, G., Liou, M.L., Liou, H.C. & Choi, Y. (1996) CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc Natl Acad Sci U S A, 93, 9699-9703.
17. Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C. & Staudt, L.M. (2008) Stromal gene signatures in large-B-cell lymphomas. New England Journal of Medicine, 359, 2313-2323.
18. Martin-Perez, D., Vargiu, P., Montes-Moreno, S., Leon, E.A., Rodriguez-Pinilla, S.M., Lisio, L.D., Martinez, N., Rodriguez, R., Mollejo, M., Castellvi, J., Pisano, D.G., Sanchez-Beato, M. & Piris, M.A. (2012) Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma. Leukemia, 26, 180-183.
19. Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., Ott, G., Rosenwald, A., Braziel, R.M., Campo, E., Vose, J.M., Lenz, G., Staudt, L.M., Chan, W.C. & Weisenburger, D.D. (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. Journal of Clinical Oncology, 29, 200-207.
20. Montes-Moreno, S., Odqvist, L., Diaz-Perez, J.A., Lopez, A.B., de Villambrosia, S.G., Mazorra, F., Castillo, M.E., Lopez, M., Pajares, R., Garcia, J.F., Mollejo, M., Camacho, F.I., Ruiz-Marcellan, C., Adrados, M., Ortiz, N., Franco, R., Ortiz-Hidalgo, C., Suarez-Gauthier, A., Young, K.H. & Piris, M.A. (2012) EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Modern Pathology, 25, 968-982.
21. Park, S., Lee, J., Ko, Y.H., Han, A., Jun, H.J., Lee, S.C., Hwang, I.G., Park, Y.H., Ahn, J.S., Jung, C.W., Kim, K., Ahn, Y.C., Kang, W.K., Park, K. & Kim, W.S. (2007) The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood, 110, 972-978.
22. Perez-Rosado, A., Artiga, M., Vargiu, P., Sanchez-Aguilera, A., Alvarez-Barrientos, A. & Piris, M. (2008) BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas. J Pathol, 214, 498-507.
23. Rimsza, L.M., Leblanc, M.L., Unger, J.M., Miller, T.P., Grogan, T.M., Persky, D.O., Martel, R.R., Sabalos, C.M., Seligmann, B., Braziel, R.M., Campo, E., Rosenwald, A., Connors, J.M., Sehn, L.H., Johnson, N. & Gascoyne, R.D. (2008) Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 112, 3425-3433.
24. Schwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H., Schaadt, M. & Diehl, V. (1982) Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature, 299, 65-67.
25. Sehn, L.H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J.J., Sutherland, J., Wilson, K.S., Gascoyne, R.D. & Connors, J.M. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Journal of Clinical Oncology, 23, 5027-5033.
26. Sehn, L.H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K.J., Shenkier, T., Sutherland, J., Gascoyne, R.D. & Connors, J.M. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-1861.
27. Seto, E., Moosmann, A., Gromminger, S., Walz, N., Grundhoff, A. & Hammerschmidt, W. (2010) Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathogens, 6, e1001063.
28. Stein, H., Mason, D.Y., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., Schwarting, R. & Lennert, K. (1985) The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood, 66, 848-858.
29. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (eds.) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
30. Wright, G., Tan, B., Rosenwald, A., Hurt, E.H., Wiestner, A. & Staudt, L.M. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A, 100, 9991-9996.